<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="12250">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00503906</url>
  </required_header>
  <id_info>
    <org_study_id>UMIAMI-20060913</org_study_id>
    <secondary_id>SCCC-2006081</secondary_id>
    <nct_id>NCT00503906</nct_id>
  </id_info>
  <brief_title>Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Bevacizumab, and Gemcitabine as First-Line Therapy in Treating Patients With Metastatic Breast Cancer</brief_title>
  <official_title>A Phase II Study of Abraxane, Bevacizumab and Gemcitabine for First Line Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami Sylvester Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Miami Sylvester Comprehensive Cancer Center</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle
      formulation and gemcitabine, work in different ways to stop the growth of tumor cells,
      either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such
      as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor
      cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing
      substances to them. Bevacizumab may also stop the growth of tumor cells by blocking blood
      flow to the tumor. Giving paclitaxel albumin-stabilized nanoparticle formulation together
      with bevacizumab and gemcitabine may kill more tumor cells.

      PURPOSE: This phase II trial is studying how well giving paclitaxel albumin-stabilized
      nanoparticle formulation together with bevacizumab and gemcitabine works as first-line
      therapy in treating patients with metastatic breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  To determine preliminary evidence of efficacy of the combination regimen of gemcitabine
           hydrochloride, paclitaxel albumin-stabilized nanoparticle formulation (Abraxane®), and
           bevacizumab as first-line treatment for Her2/neu-negative metastatic (stage IV) breast
           cancer.

      Secondary

        -  To determine the partial, complete, and overall response rate.

        -  To determine the safety and side effect profile of the treatment combination.

        -  To explore the relationship between circulating tumor cells (CTC) and disease
           progression, by measuring CTC at baseline and over the course of treatment.

      OUTLINE: Patients receive gemcitabine hydrochloride IV over 30 minutes followed by
      paclitaxel albumin-stabilized nanoparticle formulation (Abraxane®) IV over 30 minutes
      followed by bevacizumab IV over 30 minutes on days 1 and 15. Courses repeat every 28 days in
      the absence of disease progression or unacceptable toxicity.

      Patients undergo tumor tissue and blood sample collection periodically for correlative
      laboratory studies. Tumor tissue samples are analyzed for secreted protein acidic rich in
      cysteine (SPARC) expression by antibody immunostaining. Blood samples are analyzed for the
      presence of circulating tumor cells by the CellSearch™ system.

      After completion of study treatment, patients are followed at 1 year and then annually
      thereafter.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Progression-free survival will be measured from the first dose date to the earliest date of documented evidence of progressive disease or the date of death due to any causes, whichever occurs first.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects Achieving 6 Month Survival</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>The percentage of subjects achieving 6 month survival, the time from date of initial Gemcitabine, Abraxane and Bevacizumab therapy to date of death. In the absence of confirmation of death, survival time will be censored to last date of follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects Achieving 12 Month Survival</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percentage of subjects achieving 12 month survival,the time from date of initial Gemcitabine, Abraxane and Bevacizumab therapy to date of death. In the absence of confirmation of death, survival time will be censored to last date of follow-up12 month survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects Achieving 18 Month Survival</measure>
    <time_frame>18 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percentage of subjects achieving 18 month survival, the time from date of initial Gemcitabine, Abraxane and Bevacizumab therapy to date of death. In the absence of confirmation of death, survival time will be censored to last date of follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects Achieving 24 Months Survival</measure>
    <time_frame>24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percentage of subjects achieving 24 month survival, the time from date of initial Gemcitabine, Abraxane and Bevacizumab therapy to date of death. In the absence of confirmation of death, survival time will be censored to last date of follow-up12 month survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship Between Circulating Tumor Cells (CTC) and Disease Progression as Measured by Presence of CTC at Baseline and Over the Course of Study Treatment</measure>
    <time_frame>Baseline, over the course of Treatment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Determine Safety and Side Effect Profile of the Treatment Combination.</measure>
    <time_frame>Over the course of study treatment.</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The descriptions and grading scales found in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 will be utilized for adverse event reporting.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Abraxane, Bevacizumab and Gemcitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Bevacizumab 10 mg/kg BW IV over 30 minutes (+/- 5 minutes). One cycle is 28 days with chemotherapy Gemcitabine, Abraxane® and Bevacizumab given on day 1 and 15 of each treatment cycle.</description>
    <arm_group_label>Abraxane, Bevacizumab and Gemcitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Gemcitabine 1500 mg/m2 BSA IV over 30 minutes (+/- 5 minutes). One cycle is 28 days with chemotherapy Gemcitabine, Abraxane® and Bevacizumab given on day 1 and 15 of each treatment cycle.</description>
    <arm_group_label>Abraxane, Bevacizumab and Gemcitabine</arm_group_label>
    <other_name>Gemzar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abraxane</intervention_name>
    <description>Abraxane® 150 mg/m2 IV over 30 minutes (+/- 5 minutes). One cycle is 28 days with chemotherapy Gemcitabine, Abraxane® and Bevacizumab given on day 1 and 15 of each treatment cycle.</description>
    <arm_group_label>Abraxane, Bevacizumab and Gemcitabine</arm_group_label>
    <other_name>Albumin-Bound Paclitaxel Formulation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Analysis of SPARC Expression</intervention_name>
    <description>A sample of tumor block will be sent to Abraxis Bioscience for analysis of SPARC expression, at a time and location to be determined by the Principal Investigator</description>
    <arm_group_label>Abraxane, Bevacizumab and Gemcitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Circulating Tumor Cells (CTC) Analysis</intervention_name>
    <description>CTC will be measured in peripheral blood, as reference to the CellSearch System. Samples will be drawn within 48 hours of the day # 1 infusion for first cycle and again within 48 hours of the day #1 infusion for every other cycle (i.e. every odd cycle).</description>
    <arm_group_label>Abraxane, Bevacizumab and Gemcitabine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Patients must meet 1 of the following criteria:

               -  Treatment-naïve with newly diagnosed Her2/neu non-overexpressing (non amplified)
                  metastatic (stage IV) breast cancer

               -  HER2/neu-negative breast cancer with metastasis diagnosed 6 or more months after
                  completing primary systemic treatment (i.e., neoadjuvant or adjuvant
                  chemotherapy)

          -  Measurable disease as defined by RECIST criteria OR evaluable disease

          -  No CNS or brain metastases

        PATIENT CHARACTERISTICS:

          -  Inclusion Criteria

               -  Pre- or postmenopausal

               -  ECOG performance status 0-1

               -  Life expectancy &gt; 3 months

               -  Female or male patients must be surgically sterilized or willing to use an
                  acceptable method of birth control for the duration of the study

               -  Neutrophils ≥ 1.5 x 10^9/L

               -  Platelets ≥ 100 x 10^9/L

               -  Hemoglobin ≥ 9.0 g/dL

               -  Serum creatinine ≤ 1.5 mg/dL

               -  Bilirubin ≤ upper limit of normal (ULN), except when caused by metastatic
                  disease

               -  ALT/AST ≤ 2.5 times ULN, except when caused by metastatic disease

               -  Urine protein:creatinine (UPC) ratio &lt; 1.0 at screening

          -  Exclusion Criteria

               -  Pregnant (positive pregnancy test) or lactating

               -  History of gastrointestinal bleeding within the past 3 months

               -  Inadequately controlled hypertension (i.e., systolic BP &gt; 150 mm Hg and/or
                  diastolic BP &gt; 100 mm Hg while on antihypertensive medications)

               -  Prior history of hypertensive crisis or hypertensive encephalopathy

               -  Peripheral neuropathy &gt; grade 1

               -  Clinical AIDS or known positive HIV serology

               -  No concurrent clinically evident malignancy except for inactive nonmelanoma skin
                  cancer, inactive cervical cancer, or other cancer for which the patient has been
                  disease-free for 5 years

               -  Unstable angina

               -  New York Heart Association class II-IV congestive heart failure

               -  History of myocardial infarction within the past 6 months

               -  History of stroke within the past 6 months

               -  Clinically significant peripheral vascular disease

               -  Evidence of bleeding diathesis or coagulopathy

               -  History of abdominal fistula, gastrointestinal perforation, or intra-abdominal
                  abscess within the past 6 months

               -  Serious nonhealing wound, ulcer, or bone fracture

               -  Serious medical or psychiatric illness that would render chemotherapy unsafe

               -  Significant traumatic injury within the past 28 days

        PRIOR CONCURRENT THERAPY:

          -  Exclusion Criteria

               -  Previous chemotherapy for metastatic breast cancer

               -  Previous treatment with gemcitabine hydrochloride

               -  Chemotherapy within 4 weeks prior to study enrollment

               -  Radiation therapy or evidence of acute effects of radiation therapy within 2
                  weeks prior to study enrollment

               -  Any major surgery or open biopsy within 4 weeks prior to study enrollment

               -  Minor surgical procedures (i.e., fine needle aspirations or core biopsies)
                  within 7 days prior to study enrollment

               -  Participation in another experimental drug study (other than a bevacizumab
                  clinical trial for cancer) within 4 weeks prior to study enrollment

               -  Anticipation of need for major surgical procedure during the course of the study

               -  Concurrent irradiation

               -  Other concurrent chemotherapy, immunotherapy, or anti-tumor hormonal therapy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan Gluck, MD, PhD, FRCPC</last_name>
    <role>Study Chair</role>
    <affiliation>University of Miami Sylvester Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Miami Sylvester Comprehensive Cancer Center - Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Lobo C, Lopes G, Baez O, Castrellon A, Ferrell A, Higgins C, Hurley E, Hurley J, Reis I, Richman S, Seo P, Silva O, Slingerland J, Tukia K, Welsh C, Glück S. Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer. Breast Cancer Res Treat. 2010 Sep;123(2):427-35. doi: 10.1007/s10549-010-1002-0. Epub 2010 Jun 29.</citation>
    <PMID>20585851</PMID>
  </results_reference>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>July 25, 2014</lastchanged_date>
  <firstreceived_date>July 17, 2007</firstreceived_date>
  <firstreceived_results_date>January 22, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IV breast cancer</keyword>
  <keyword>recurrent breast cancer</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Abraxane, Bevacizumab and Gemcitabine</title>
          <description>This is a single arm study</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Single Arm</title>
          <description>This is a single arm study</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="30"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="27"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="3"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="52.3" spread="9.2"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="53.8" lower_limit="34" upper_limit="69"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="29"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>American Indian or Alaska Native</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Asian</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Native Hawaiian or Other Pacific Islander</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Black or African American</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="8"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>White</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="20"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>More than one race</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Unknown or Not Reported</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="30"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression-free Survival</title>
        <description>Progression-free survival will be measured from the first dose date to the earliest date of documented evidence of progressive disease or the date of death due to any causes, whichever occurs first.</description>
        <time_frame>6 months</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Single Arm</title>
            <description>This is a single arm study</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="29"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Progression-free Survival</title>
            <description>Progression-free survival will be measured from the first dose date to the earliest date of documented evidence of progressive disease or the date of death due to any causes, whichever occurs first.</description>
            <units>percentage of particpants</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="93.1" lower_limit="77" upper_limit="99"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects Achieving 6 Month Survival</title>
        <description>The percentage of subjects achieving 6 month survival, the time from date of initial Gemcitabine, Abraxane and Bevacizumab therapy to date of death. In the absence of confirmation of death, survival time will be censored to last date of follow-up</description>
        <time_frame>6 months</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Abraxane, Bevacizumab and Gemcitabine</title>
            <description>This is a single arm study</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="29"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentage of Subjects Achieving 6 Month Survival</title>
            <description>The percentage of subjects achieving 6 month survival, the time from date of initial Gemcitabine, Abraxane and Bevacizumab therapy to date of death. In the absence of confirmation of death, survival time will be censored to last date of follow-up</description>
            <units>percentage of particpants</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="92.9" lower_limit="74.3" upper_limit="98.2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects Achieving 12 Month Survival</title>
        <description>Percentage of subjects achieving 12 month survival,the time from date of initial Gemcitabine, Abraxane and Bevacizumab therapy to date of death. In the absence of confirmation of death, survival time will be censored to last date of follow-up12 month survival</description>
        <time_frame>12 months</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Single Arm</title>
            <description>This is a single arm study</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="29"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentage of Subjects Achieving 12 Month Survival</title>
            <description>Percentage of subjects achieving 12 month survival,the time from date of initial Gemcitabine, Abraxane and Bevacizumab therapy to date of death. In the absence of confirmation of death, survival time will be censored to last date of follow-up12 month survival</description>
            <units>percentage of participants</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="84.9" lower_limit="64.5" upper_limit="94.1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects Achieving 18 Month Survival</title>
        <description>Percentage of subjects achieving 18 month survival, the time from date of initial Gemcitabine, Abraxane and Bevacizumab therapy to date of death. In the absence of confirmation of death, survival time will be censored to last date of follow-up</description>
        <time_frame>18 months</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Single Arm</title>
            <description>This is a single arm study</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="29"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentage of Subjects Achieving 18 Month Survival</title>
            <description>Percentage of subjects achieving 18 month survival, the time from date of initial Gemcitabine, Abraxane and Bevacizumab therapy to date of death. In the absence of confirmation of death, survival time will be censored to last date of follow-up</description>
            <units>percentage of participants</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="77.2" lower_limit="51.1" upper_limit="90.5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects Achieving 24 Months Survival</title>
        <description>Percentage of subjects achieving 24 month survival, the time from date of initial Gemcitabine, Abraxane and Bevacizumab therapy to date of death. In the absence of confirmation of death, survival time will be censored to last date of follow-up12 month survival</description>
        <time_frame>24 months</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Abraxane, Bevacizumab and Gemcitabine</title>
            <description>This is a single arm study</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="29"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentage of Subjects Achieving 24 Months Survival</title>
            <description>Percentage of subjects achieving 24 month survival, the time from date of initial Gemcitabine, Abraxane and Bevacizumab therapy to date of death. In the absence of confirmation of death, survival time will be censored to last date of follow-up12 month survival</description>
            <units>percentage of participants</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="61.7" lower_limit="25.4" upper_limit="84.4"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relationship Between Circulating Tumor Cells (CTC) and Disease Progression as Measured by Presence of CTC at Baseline and Over the Course of Study Treatment</title>
        <time_frame>Baseline, over the course of Treatment</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Determine Safety and Side Effect Profile of the Treatment Combination.</title>
        <description>The descriptions and grading scales found in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 will be utilized for adverse event reporting.</description>
        <time_frame>Over the course of study treatment.</time_frame>
        <safety_issue>Yes</safety_issue>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Single Arm</title>
          <description>This is a single arm study</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukopenia</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Breast Abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Fever/Sepsis</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Neutropenic Fever</sub_title>
                <description>Grade 4</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral Neuropathy</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Seizure/Syncope</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hematuria</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>UTI</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Shortness of breath</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>PortAcath infection</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Tamponade</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Lymphedema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Tricuspid Regurg</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Heat intolerance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Hot flashes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurred Vision</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Scotoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Heartburn</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Reflux</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Regurgitation (valve)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Weight Loss</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Flu-like symptoms</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Oral infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Rhinorrhea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Mucositis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Painful edema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Pedal edema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Loss of appetite</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bone Pain</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Hand/Foot syndrome</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral Neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute renal insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Amenorrhea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Shortness of breath</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Skin rash/lesion</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>PortAcath Disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Skin discoloration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Thrombus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Stefan Gluck MD</name_or_title>
      <organization>UM/Sylvester Comprehensive Cancer CEnter</organization>
      <phone>305-243-4909</phone>
      <email>sgluck@med.miami.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
